UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 37

Sortiert nach

Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low/intermediate‐1–risk myelodysplastic syndrome and thrombocytopenia

Cancer, 2014-06, Vol.120 (12), p.1838-1846

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

Blood, 2010-10, Vol.116 (17), p.3163-3170

2010

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia

Journal of clinical oncology, 2010-01, Vol.28 (3), p.437-444

2010

Link zum Volltext

Verfügbarkeit prüfen

Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes

Diabetes care, 2005-11, Vol.28 (11), p.2686-2690

2005

Link zum Volltext

Verfügbarkeit prüfen

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

Journal of hematology and oncology, 2012-11, Vol.5 (1), p.71-71, Article 71

2012

Link zum Volltext

Verfügbarkeit prüfen

Evidence for a Locus on Chromosome 1 That Influences Vulnerability to Alcoholism and Affective Disorder

The American journal of psychiatry, 2001-05, Vol.158 (5), p.718-724

2001

Link zum Volltext

Verfügbarkeit prüfen

Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Journal of clinical oncology, 2016-12, Vol.34 (36), p.4381-4389

2016

Link zum Volltext

Verfügbarkeit prüfen

Semi parametric frailty models for zero-inflated event count data in the presence of informative dropout

Biometrics, 2019-09, Vol.75 (4), p.1168-1178

2019

Link zum Volltext

Verfügbarkeit prüfen

Modeling event count data in the presence of informative dropout with application to bleeding and transfusion events in myelodysplastic syndrome: G. DIAO ET AL

Statistics in medicine, 2017-09, Vol.36 (22), p.3475-3494

2017

Link zum Volltext

Verfügbarkeit prüfen

Semiparametric frailty models for zero‐inflated event count data in the presence of informative dropout

Biometrics, 2019-12, Vol.75 (4), p.1168-1178

2019

Link zum Volltext

Verfügbarkeit prüfen

Bayesian design of biosimilars clinical programs involving multiple therapeutic indications

Biometrics, 2020-06, Vol.76 (2), p.630-642

2020

Link zum Volltext

Verfügbarkeit prüfen

Modeling event count data in the presence of informative dropout with application to bleeding and transfusion events in myelodysplastic syndrome

Statistics in medicine, 2017-09, Vol.36 (22), p.3475-3494

2017

Link zum Volltext

Verfügbarkeit prüfen

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine

Leukemia & lymphoma, 2013-02, Vol.54 (2), p.321-328

2013

Link zum Volltext

Verfügbarkeit prüfen

Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data

Advances in therapy, 2017-01, Vol.34 (1), p.148-155

2017

Link zum Volltext

Verfügbarkeit prüfen

Hypothesis testing for two-stage designs with over or under enrollment

Statistics in medicine, 2015-07, Vol.34 (16), p.2417-2426

2015

Link zum Volltext

Verfügbarkeit prüfen

Reply to Comments

Statistics in medicine, 2016-04, Vol.35 (9), p.1560-1560

2016

Link zum Volltext

Verfügbarkeit prüfen

OR27-4 Placebo-Controlled and Open-Label Extension Study of a Novel Hepatic-Targeted Antisense Cimdelirsen (IONIS-GHR-LRx) Under Investigation in Acromegaly Patients

Journal of the Endocrine Society, 2022-11, Vol.6 (Supplement_1), p.A526-A526

2022

Link zum Volltext

Verfügbarkeit prüfen

Improving the power to establish clinical similarity in a Phase 3 efficacy trial by incorporating prior evidence of analytical and pharmacokinetic similarity

Journal of biopharmaceutical statistics, 2018-03, Vol.28 (2), p.320-332

2018

Link zum Volltext

Verfügbarkeit prüfen

Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx: Results of Phase 1 and Phase 2 Studies

JACC. Basic to translational science, 2021-06, Vol.6 (6), p.485-496

2021

Link zum Volltext

Verfügbarkeit prüfen

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes

Cancer, 2011-03, Vol.117 (5), p.992-1000

2011

Link zum Volltext

Verfügbarkeit prüfen

Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome

Biometrics, 2014-12, Vol.70 (4), p.1003-1013

2014

Link zum Volltext

Verfügbarkeit prüfen

Antisense Inhibition of Angiotensinogen With IONIS-AGT-L Rx : Results of Phase 1 and Phase 2 Studies

JACC. Basic to translational science, 2021-06, Vol.6 (6), p.485

2021

Link zum Volltext

Verfügbarkeit prüfen

Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx

JACC. Basic to translational science, 2021-06, Vol.6 (6), p.485-496

2021

Link zum Volltext

Verfügbarkeit prüfen

Multivariate Recurrent Events in the Presence of Multivariate Informative Censoring with Applications to Bleeding and Transfusion Events in Myelodysplastic Syndrome

Journal of biopharmaceutical statistics, 2014-03, Vol.24 (2), p.429-442

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(37)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(22)
Life Sciences & Biomedicine
(20)
Humans
(19)
Female
(12)
Male
(12)
Middle Aged
(10)
Aged
(8)
Biological And Medical Sciences
(8)
Physical Sciences
(8)
Mathematics
(7)
Medical Sciences
(7)
Oncology
(7)
Statistics & Probability
(7)
Treatment Outcome
(7)
Adult
(6)
Aged, 80 And Over
(6)
Clinical Trials
(6)
Myelodysplastic Syndromes - Drug Therapy
(6)
Computer Simulation
(5)
Double-Blind Method
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low/intermediate‐1–risk myelodysplastic syndrome and thrombocytopenia

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia

Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

Evidence for a Locus on Chromosome 1 That Influences Vulnerability to Alcoholism and Affective Disorder

Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Semi parametric frailty models for zero-inflated event count data in the presence of informative dropout

Modeling event count data in the presence of informative dropout with application to bleeding and transfusion events in myelodysplastic syndrome: G. DIAO ET AL

Semiparametric frailty models for zero‐inflated event count data in the presence of informative dropout

Bayesian design of biosimilars clinical programs involving multiple therapeutic indications

Modeling event count data in the presence of informative dropout with application to bleeding and transfusion events in myelodysplastic syndrome

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine

Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data

Hypothesis testing for two-stage designs with over or under enrollment

Reply to Comments

OR27-4 Placebo-Controlled and Open-Label Extension Study of a Novel Hepatic-Targeted Antisense Cimdelirsen (IONIS-GHR-LRx) Under Investigation in Acromegaly Patients

Improving the power to establish clinical similarity in a Phase 3 efficacy trial by incorporating prior evidence of analytical and pharmacokinetic similarity

Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx: Results of Phase 1 and Phase 2 Studies

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes

Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome

Antisense Inhibition of Angiotensinogen With IONIS-AGT-L Rx : Results of Phase 1 and Phase 2 Studies

Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx

Multivariate Recurrent Events in the Presence of Multivariate Informative Censoring with Applications to Bleeding and Transfusion Events in Myelodysplastic Syndrome

Initial Results from a Phase 2 Study of Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Suchergebnisse filtern